Pfizer Ltd

Pfizer Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Pfizer Ltd

₹ 4,532 -0.15%
08 Jul - close price
pfizerindia.com BSE: 500680 NSE: PFIZER
About

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1]
It is the 3rd largest multinational pharmaceutical company in India.[2]

Key Points

Parentage
The company is a subsidiary of Pfizer Inc. one of the world’s leading biopharma companies with a presence in over 125 countries. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. [1] [2]

Website BSE NSE
  • Market Cap ₹ 20,733 Cr.
  • Current Price ₹ 4,532
  • High / Low ₹ 5,879 / 4,360
  • Stock P/E 135
  • Book Value ₹ 302
  • Dividend Yield 1.65 %
  • ROCE 27.2 %
  • ROE 19.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 33.2%

Cons

  • Stock is trading at 15.0 times its book value
  • Earnings include an other income of Rs.512 Cr.
  • Working capital days have increased from 60.8 days to 135 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty 500 Nifty MidSmallcap 400 Nifty Smallcap 250 Nifty 500 Multicap 50:25:25

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Nov 2006 Nov 2007 Nov 2008
664 676 678
537 815 760
Operating Profit 127 -139 -82
OPM % 19% -21% -12%
48 600 512
Interest 0 0 -0
Depreciation 13 10 11
Profit before tax 163 451 419
Tax % 35% 25% 29%
106 340 300
EPS in Rs 35.64 113.94 100.39
Dividend Payout % 63% 24% 12%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 0%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 6%
Stock Price CAGR
10 Years: 9%
5 Years: -5%
3 Years: 6%
1 Year: -20%
Return on Equity
10 Years: %
5 Years: %
3 Years: 24%
Last Year: 20%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Nov 2006 Nov 2007 Nov 2008
Equity Capital 30 30 30
Reserves 376 620 871
-0 -0 -0
240 218 197
Total Liabilities 646 867 1,098
65 60 51
CWIP 2 10 32
Investments -0 0 0
579 797 1,014
Total Assets 646 867 1,098

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Nov 2006 Nov 2007 Nov 2008
123 17 238
7 232 -79
-34 -76 -95
Net Cash Flow 97 173 64
Free Cash Flow 120 283 213
CFO/OP 148% -93% -446%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Nov 2006 Nov 2007 Nov 2008
Debtor Days 38 33 32
Inventory Days 160 149 190
Days Payable 208 144 164
Cash Conversion Cycle -10 39 58
Working Capital Days 2 45 135
ROCE % 37% 27%

Insights

In beta
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Prevenar 13 market share in private pneumococcal vaccines market
%

Log in to view insights

Please log in to see hidden values.

Login
Corex Dx market share in dry cough market
%
Number of dealers/distributors
count
Pacitane market share in therapeutic category
%
HCPs prescribing Internal Medicine brands
count
Eliquis market share in NOAC category
%
Minipress XL market share in uncontrolled hypertension market
%
Meronem unit sales growth
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92%
2.81% 2.82% 3.03% 3.32% 3.22% 3.54% 2.74% 2.18% 2.40% 2.60% 2.71% 2.81%
14.89% 15.00% 15.15% 15.32% 15.83% 16.03% 16.80% 17.10% 17.23% 17.11% 17.05% 16.89%
18.37% 18.24% 17.87% 17.42% 17.00% 16.50% 16.54% 16.79% 16.45% 16.37% 16.32% 16.36%
No. of Shareholders 1,15,9881,16,9481,12,4561,09,2141,06,09898,8241,05,0151,08,2611,03,2221,03,4801,00,93399,545

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls